Merus NV (MRUS) Given Consensus Rating of “Buy” by Brokerages

Merus NV (NASDAQ:MRUS) has been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $30.67.

A number of brokerages have recently commented on MRUS. BidaskClub cut Merus from a “buy” rating to a “hold” rating in a research note on Saturday. Wedbush reiterated an “outperform” rating and issued a $34.00 price target (up from $26.00) on shares of Merus in a research note on Friday, July 27th. Zacks Investment Research cut Merus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 3rd. Finally, ValuEngine upgraded Merus from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Deutsche Bank AG lifted its stake in shares of Merus by 146.6% in the 4th quarter. Deutsche Bank AG now owns 9,400 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 5,588 shares during the last quarter. Stanley Laman Group Ltd. lifted its stake in shares of Merus by 23.7% in the 2nd quarter. Stanley Laman Group Ltd. now owns 57,396 shares of the biotechnology company’s stock valued at $1,306,000 after acquiring an additional 10,982 shares during the last quarter. Millennium Management LLC bought a new position in shares of Merus in the 1st quarter valued at $267,000. Sofinnova Ventures Inc bought a new position in shares of Merus in the 1st quarter valued at $36,338,000. Finally, BVF Inc. IL bought a new position in shares of Merus in the 1st quarter valued at $44,832,000. Institutional investors own 43.31% of the company’s stock.

Merus traded down $0.42, hitting $18.81, on Friday, according to MarketBeat.com. 19,171 shares of the company’s stock were exchanged, compared to its average volume of 40,066. Merus has a 52 week low of $13.30 and a 52 week high of $26.74. The stock has a market capitalization of $435.07 million, a PE ratio of -4.38 and a beta of -0.14.

Merus (NASDAQ:MRUS) last released its earnings results on Thursday, July 26th. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.33. Merus had a negative return on equity of 69.13% and a negative net margin of 170.74%. The firm had revenue of $11.84 million during the quarter, compared to analysts’ expectations of $3.47 million. equities research analysts expect that Merus will post -3.09 earnings per share for the current year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply